Справочник Под редакцией академика ран а. С. Тиганова Справочник психиатра правкиШульман indd 1 30. 10. 2015 11 21 32
 Скачать 3.64 Mb.
|
|
590 Литература Brodie M. Do we need any more antiepileptic drugs? // Epilepsy Research. — 2001. — Vol. 45. — P. 3–6. Brodie M. Zonisamide as adjunctive therapy for refractory partial seizures // Epilepsy Research. — 2006. — Vol. 68. — P. 11–16. Brodie M.J., Shorvon S.D., Canger R. et al. Commission on European Aff airs: appropriate standards of epilepsy care across // Europe Epilepsia. — 1997. — Vol. 38. — P. 1245–1250. Burke M.J., Preskorn S.H. Standard antidepressant pharmacotherapy for the acute treat- ment of mood disorders. Back to psychopharmacology-the forth generation of progress. Epub. 2000. Burton L.A., Harden C. Eff ect of topiramate on attention // Epilepsy Research. — 1997. — Vol. 27. — P. 29–32. Сarlsson A., Lindqvist M. Eff ect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain // Acta Pharmacol. — Vol. 20. — P. 140–144. Casanova M.F. et al. Th e neuropathology of autism: A review of the current linera- ture // Th e Siberian Journal of Special Education. — 2012. — № 2 (6). Cereghino J.J., Biton V., Abou-Khalil B. et al. Levetiracetam for partial seizures. Results of double-blind, randomized clinical trial // Neurology. — 2000. — Vol. 55. — P. 236–242. Сlinical Guideline 22 Anxiety: management of anxiety (panic disorder, with or without agoraphobia, and generalized anxiety disorder) in adults in primary, secondary and com- munity care. April 2007. Cloninger R.C. Predisposition and issues of mixted etiology in psychogenic move- ment disorders // Psychogenic movement disorders and other conversion disorders / Eds. М. Hallet, A.E. Lang, J. Janckovic et al. — 2011. — P. 33–37. Crome L., Stern J. Pathology of Mental Retardation. — Edinburgh, London, 1972. — 544 p. Damasio A.R., Anderson S.W. Th e Frontal Lobes // In: Clinical neuropsychology / Eds. K. Heilman, E. Valenstein. — Oxford: Oxford University Press, 2003. — P. 404–446. Devinsky O., Elger C. Effi cacy of levetiracetam in partial seizures // Epileptic Disor- der. — 2003. — Vol. 5 (Suppl. 1). — P. 27–31. Dooley M., Plosker G.L. Levetiracetam. A review of its adjunctive use in the manage- ment of partial onset seizures // Drugs. — 2000. — Vol. 60. — № 4. — P. 871–893. Edlund A., Lundstrom M., Doucet L. et al. Symptom profi le of delirium in older people with and without dementia // J. Geriatric Psychiatry and Neurology. — 2007. — Vol. 20. — P. 166. Erhardt S., Schwieler L., Nilsson L., Linderholm K., Engberg G. Th e kynurenik acid hy- pothesis of schizophrenia // Physiol. Behav. — Vol. 92. — № 1–2. — P. 203–209. Fountoulakis K.N., Vieta E., Siamouli M. Treatment of bipolar disorder: a complex treat- ment for a multi-facet disorder // Ann. Gen. Psychiatry. — 2007. — Vol. 9. — № 6 (1). — P. 27. French J.A., Krauss G.L., Bito V. et al. Adjunctive perampanel for refractory partial-on- set seizures: Randomized phase III study 304 // Neurology. — 2012. — Vol. 79. — № 6. — P. 589–596. Genton P., Gelisse P. Antimyoclonic eff ect of levetiracetam // Epileptic Disorders. — 2000. — Vol. 2. — P. 209–212. Gil-Nagel A. Review of new antiepileptic drugs as initial therapy // Epilepsia. — 2003. — Vol. 44 (Suppl. 4). — P. 3–10. Справочник психиатра_правки-Шульман.indd 590 30.10.2015 11:21:45 Литература 591 Goodwin F.K., Jamison K.R. Manic-depressive Illness, Bipolar Disorders and recurrent Depression. — 2nd ed. — Oxford: University press, 2007. — 1238 p. Goodwin G.M., Anderson I. et al. ECNP consensus meeting. Bipolar depression. Nice, March 2007 // Eur. Neuropsychopharmacol. — 2008. — Vol. 18. — № 7. — P. 535–549. Gower A.J., Noyer M., Verloes R. et al. UCB L059, a novel anti-convulsant drug: phar- macological profi le in animals // Eur. J. Pharmacology. — 1992. — Vol. 222. — P. 193–203. Guay D. Drug treatment of paraphilic and nonparaphilic sexual disorders // Clinical Th erapeutics. — 2009. — Vol. 31. — № 1. — P. 1−31. Hafner H., Heiden W. Epidemiology of Schzophrenie // Canadian Journal of Psychia- try. — 1997. — Vol. 42. — P. 139−151. Hanon E., Klitgaard H. Neuroprotective properties of the novel antiepileptic drug le- vetiracetam in the rat middle cerebral artery occlusion model of focal cerebral ischemia // Seizure. — 2001. — Vol. 10. — P. 287–293. Hanson D.R., Gottesman I.I. Th eories of schizophrenia: a genetic-infl ammatory-vascu- lar synthesis // BMC Medical Genetics. — 2005. — Vol. 6. — P. 7. [Pub Med: http://www. biomedcentral/com /1471–2350/6/7/]. Hauser W.A. Incidence and prevalence // Epilepsy: A Comprehensive Textbook / Eds. J. Engel, T.A. Pedley. — Philadelphia: Lippincott-Raven, 1998. — P. 47–57. Heresco-Levy U., Javitt D.C. Th e role of NMDA-receptor-mediated neurotransmission in the patophysiology and therapeutics of psychiatric syndromes // Eur. Neuropsychophar- macology. — 1998. — Vol. 8. — P. 141–152. Hirsch E., Schmitz B., Carreňo M. Epilepsy, antiepileptic drugs (AEDs) and cognition // Acta Neurologica Scand. — 2003. — Vol. 108 (Suppl. 180). — P. 23–32. Jaff e О.Р. Drug Dependence: opioids, nonnarcotics, nicotine (tobacco), and caff eine // Comprehensive Textbook of Psychiatry / Eds. H.I. Kaplan, B.J. Sadock. — 5 th ed.— Balti- mor, 1989. — Vol. 1. — P. 642–686. Jones K.L. Smith’s recognizable patterns of human malformation. — Philadelphia, 2006. — 954 p. Kalinin V. Suicidality and antiepileptic drugs. Is there a link? // Drug Safety. — 2007. — Vol. 30. — № 2. — P. 123–142. Kalsekar I., Wagner J.S., Dibonaventura M. Comparison of health-related quality of life among patients using atypicalantipsychotics for treatment of depression: results from the Na- tional Health and Wellness Survey // Health Qual Life Outcomes. — 2012. — Vol. 10. — P. 81. Kane J.M. Schizophrenia // New Engl. J. Med. — 1996. — Vol. 334. — № 1. — P. 34–41. Kapur S., Mamo D. Half a century of antipsychotics and still a central role for dopa- mine D2 receptors // Prog. Neuropsychopharmacol. Biol. Psychiatry. — 2003. — Vol. 27. — № 7. — P. 1081–1090. Kantor S.J. Imipramine equivalents // J. Clin. Psychiatry. — 1990. — Vol. 51. — № 6. — P. 257. Kasteleijn-Nolst D.G.A., Hirsch E. Levetiracetam: preliminary effi cacy in generalized seizures // Epileptic Disorders. — 2003. — Vol. 5 (Suppl. 1). — S39–S44. Kessler R.C., Angermeyer M., Anthone J.C. et al. Lifetime prevalence and age-of-onset distributions of mental disorders in the World Health Organizations World Mental Health Survey Initiative // World Psychiatry. — 2007. — Vol. 6. — P. 168–176. Ketter T.A., Post R.M., Th eodore W.H. Positive and negative psychiatric eff ects of antiepi- leptic drugs in patients with seizure disorders // Neurology. — 1999. — Vol. 53 (Suppl. 2). — P. 53–67. Справочник психиатра_правки-Шульман.indd 591 30.10.2015 11:21:45 592 Литература King M. et al. Prevalence of common mental disorders in general practice attendees across Europe // Th e British Jornal of Psychiatry. — 2008. — Vol. 192. — P. 362–367. Klitgaard H., Matagne A., Gobert J. et al. Evidence for unique profi le of levitiracetam in rodent models of seizure and epilepsy // Eur. J. Pharmacology. — 1998. — Vol. 353. — P. 191–206. Klitgaard H., Pitkänen A. Antiepileptogenesis, neuroprotection, and disease modifi ca- tion in the treatment of epilepsy: focus on levetiracetam // Epileptic Disorders. — 2003. — Vol. 5 (Suppl. 1). — S9–S16. Krauss G.L., Betts T., Abou-Khalil B. et al. Levetiracetam treatment of idiopathic gene- ralized epilepsy // Seizure. — 2003. — Vol. 12. — P. 617–620. Kwan P., Brodie M. Early identifi cation of refractory epilepsy // N. Engl. J. Med. — 2000. — Vol. 342. — P. 314–319. Leonhard K. Систематика эндогенных психозов и их дифференцированная этиология: Пер. с нем. / Под ред. А.С. Тиганова. — М.: Практическая медицина, 2010. — 456 с. Leonhard K. Auft eilung Der endogenen Psychsen und Ihre Diff erenziette Atiologie. — Berlin: Akademie-Verlag, 1986. Li Y.F., Liu Y.Q., Huang W.C., Luo Z.P. Cytoprotective eff ect is one of common action path- ways for antidepressants // Acta Pharmacol. Sin. — 2003. — Vol. 24. — № 10. — P. 996–1000. Lord C., Rutter M., LeCouteur A. Autism Diagnostic Interview — Revised: A revised version of a diagnostic interview for caregivers of individuals with possible pervasive de- velopmental disorder // J. of Autism and Developmental Disorders. — 1994. — Vol. 24. — P. 659–685. Löscher W., Hönack D., Rundfeldt C. Antiepileptogenic eff ects of the novel anticonvul- sant levetiracetam (ucb L059) in the kindling model of temporal lobe epilepsy // J. Pharma- col. Exp. Th er. — 1998. — Vol. 284. — № 2. — P. 474–479. Löscher W., Jäckel R., Czuczwar S. Is amygdala kindling in rats a model for drug-resis- tant partial epilepsy? // Exp. Neurology. — 1986. — Vol. 93. — P. 211–226. Lovaas J.I. Behavioral treatment and normal educational and intellectual functioning in young autistic children // J. of Consulting and Clinical Psychology. — 1987. — Vol. 55. — P. 3–9. Maksakova O., Gusarova S., Ignatieva N. et al. Rehabilitation Team and Consciousness Restoration // Proc. of 6th World Congress of Neurorehabilitation. — Vienna (Austria), 2010. — P. 197–203. —M321C0302 [Ed. by MEDIMOND s.r.l. 2010]. Margineanu D.C., Klitgaard H. Inhibition of neuronal hypersynchrony in vitro dif- ferentiates levetiracetam from classical antiepileptic drugs // Pharmacol. Res. — 2000. — Vol. 42. — P. 281–285. Marneros A. Das neue Handbuch der bipolaren und depressiven Erkrankungen. — Stuttgart; New-York: Th ieme Verlag, 2004. — Vol. 781. Masur H. Scales and scores in neurology. — Stuttgart: Th ieme, 2004 — 488 p. Mayer-Gross W., Slater E., Roth M. Clinical psychiatry. — London, 1960. McNamara J.O. Kindling: an animal model of complex partial epilepsy // Ann. Neuro- logy. — 1984. — Vol. 16 (Suppl.). — S72–S76. Merckelbach H., Horselenberg R., Muris P. Th e creative experiences questionnaire (CEQ): a brief sef-report measure of fantasy proneness // Personality and individual Diff e- rences. — 2001. — Vol. 32. — P. 695–705. Справочник психиатра_правки-Шульман.indd 592 30.10.2015 11:21:45 Литература 593 Meyer-Lindenberg A. Introduction to topic: Autism spectrum disorders // Der Nerve- narzt. — 2011. — № 5. — P. 551–552. Mitchell T.N., Sander J.W. Levetiracetam. A new antiepileptic drug for the adjunctive therapy of chronic epilepsy // Drugs of Today. — 2001. — Vol. 37. — № 10. — P. 665–673. Moertl K., Buchholz M., Lamott F. Gender constructions of male sex off enders in Germany: narrative analysis from group psychotherapy // Arch. Sex Behav. — 2010. — Vol. 39. — № 1. — P. 203−212. Mohanraj R., Parker P.G., Stephen L.J., Brodie M.J. Levetiracetam in refractory epilepsy: a prospective observational study // Seizure. — 2005. — Vol. 14. — P. 23−27. Moskowitz A., Schäfer I., Dorahy M.J. Psychosis, trauma and dissociation. Emerging perspectives on severe psychopathology. — 2009. — 358 p. Noyer M., Gillard M., Matagne A. et al. Th e novel antiepileptic drug levetiracetam (UCB L059) appears to act via a specifi c binding site in CNS membranes // Eur. J. Pharma- cology. — 1995. — Vol. 286. — P. 137–146. Ostling S., Skoog I. Psychotic symptoms and paranoid ideation in a non-demented population based sample of the very old // Archives of General Psychiatry. — 2002. — Vol. 59. — P. 53–59. O’Reilly G., Carr A., Murphy P., Cotter A. A controlled evaluation of a prison-based se- xual off ender intervention program // Sex Abuse. — 2010. — Vol. 22. — № 1. — P. 95–111. Ortinski P., Meador K.J. Cognitive side eff ects of antiepileptic drugs // Epilepsy and Behavior. — 2004. — Vol. 5 (Suppl. 1). — P. 60–65. Patsalos P.N. Pharmacokinetic profi le of levetiracetam: Toward ideal characteristics // Pharmacol. Th er. — 2000. — Vol. 85. — P. 77–85. Patsalos P.N., Walker M.C., Ratnaraj N. et al. Th e pharmacokinetics of levetiracetam (UCB l059) in patients with intractable epilepsy // Epilepsia. — 1995. — Vol. 36 (Suppl. 4). — P. 52. Pellock J.M., Glauser T.A., Bebin E.M. et al. Pharmacokinetic study of levetiracetam in children // Epilepsia. — 2001. — Vol. 42. — № 12. — P. 1574–1579. Perucca E. Pharmacologic advantages of antiepileptic drug monotherapy // Epilep- sia. — 1997. — Vol. 38 (Suppl. 5). — P. 6–8. Perucca E., Johannesen S. Th e ideal pharmacokinetic properties of an antiepileptic drug: how close does levetiracetam come? // Epileptic Disorders. — 2003. — Vol. 5 (Suppl. 1). — S17–S26. Rapoport J.L., Addington A.M., Frangou S., Psych M.R. Th e neurodevelopmental model of schizophrenia: update 2005 // Mol. Psychiatry. — 2005. — Vol. 10. — № 5. — P. 434–449. Rapoport J.A. at al. Autizm spectrum disorders and childhood-onset Shizophrenia: clinical and biological contributions to a relation revisited // J. Am. Acad. Child. Adolesc. Psychiatry. — 2009. — Vol. 48. — № 1. — P. 8–10. Reijs R., Aldenkampf A.P., De Krom M. Mood eff ects of antiepileptic drugs // Epilepsy and Behavior. — 2004. — Vol. 5 (Suppl. 1). — P. 66–76. Remschmidt H., Th eisen F.V. Schzophrenie and Related Disorderers in Children and Adolescents // J. of Neural Transmission Supplement. — 2005. — Vol. 69. Richelson E. Preclinical pharmacology of neuroleptics: focus on new generation com- pounds // J. Clin. Psychiatry. — 1996. — Vol. 57 (Suppl. 11). — P. 4–11. Roberts G., Majoie H., Leenen L. et al. Ketter’s hypothesis of mood eff ects of antiepilep- tic drugs coupled to the mechanism of action of topiramate and levetiracetam // Epilepsy and Behavior. — 2005. — Vol. 6. — P. 366–372. Справочник психиатра_правки-Шульман.indd 593 30.10.2015 11:21:45 594 Литература Rogawski M.A., Hanada T. Preclinical pharmacology of perampanel, a selective non-competitive AMPA-receptor antagonist // Acta Neurol. Scand. — 2013. — Vol. 127 (Suppl. 197). — P. 19–24. Rossler W., Salize H.J. et al. Size of burden of schizophrenia and psychotic disorders // European Neuropsychopharm. — 2005. — Vol. 15. — P. 399–409. Saleh F., Guidry L. Psychosocial and Biological Treatment Considerations for the Paraphilic and Nonparaphilic Sex Off ender // J. Am. Acad. Psychiatry Law. — 2003. — Vol. 31. — P. 486–493. Schatzberg A.F., Nemeroff C.B. Th e American psychiatric publishing textbook of psy- chopharmacology. — 4th ed. Schmidt D., Gram L. Monotherapy versus polytherapy in epilepsy. A reappraisal // CNS Drugs. — 1995. — Vol. 3. — № 3. — P. 194–208. Seeman P. Atypical antipsychotics: mechanism of action // Can. J. Psychiatry. — 2002. — Vol. 47. — № 1. — P. 27–38. Sharief M.K., Singh P., Sander J.W. et al. Effi cacy and tolerability study of ucb LO59 in patients with refractory epilepsy // J. Epilepsy. — 1996. — Vol. 9. — P. 106–112. Sills G.L., Leach J.P., Fraser C.M. et al. Neurochemical studies with the novel anticon- vulsant levetiracetam in mouse brain // Eur. J. Pharmacology. — 1997. — Vol. 325. — P. 35–40. Schopler E., Mesibov G.В., Hearsey K. Structured teaching in the TEACCH system // In: Learning and cognition in autism. Current issues in autism / Eds. E. Schopler, G.B. Mesi- bov. — New York: Plenum Press, 1995. — P. 243–268. Schopler E., Reichler R.J., Renner B.R. Th e Children Autism Rating Scale (CARS) // Los Angeles, CA: Western Psychological Services, 1988. — P. 1–6. Schopler E., Reichler R.J., Lansing, M. Strategien der Entwicklungsforderung fur Eitern, Padagogen und Th e-rapeuten. — Verlag Modernes Lernen, Dortmund, 1983. Shorvon S., Löwenthal A., Janz D. et al. Multicenter double-blind, randomized, place- bo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures // Epilepsia. — 2000. — Vol. 41. — № 9. — P. 1179–1186. Sunderland A., Harris J.E., Gleave J. Memory failures in everyday life following severe head injury // J. Clin. Neuropsychology. — 1984. — Vol. 6. — P. 127–142. Teasdale P., Jennett B. Assessment of coma and impaired consciousness. A practical scale // Lancet. — 1974. — Vol. 2. — № 13. — P. 81–84. Th ompson P.J., Baxendale S.A., Duncan J.S. et al. Eff ects of topiramate on cognitive function // J. Neurol. Neurosurg. Psychiatry. — 2000. — Vol. 69. — P. 636–641. Virani A.S., Bezchlibnyk-Butler K.Z., Jeff ries J.J. Clinical handbook of psychotropic drugs. — 18 th revised version. — Ashland, OH: Hogrefe and Huber Publishers, 2009. Walker M.C., Patsalos P.N. Clinical pharmacokinetics of new antiepileptic drugs // Pharmacol. Th er. — 1995. — Vol. 67. — P. 351–384. Walker M.C., Sander J.W. New anti-epileptic drugs // Exp. Opin. Invest. Drug. — 1999. — Vol. 8. — P. 1497–1510. Walker M.C., Sander J.W.A.S. Th e impact of the new antiepileptic drugs on the prog- nosis of epilepsy. Seizure freedom should be the ultimate goal // Neurology. — 1996. — Vol. 46. — P. 912–914. Weinberger D.R. On the plausibility of «the neurodevelopmental hypothesis» of schizo- phrenia // Neuropsychopharmacology. — 1996. — Vol. 14 (Suppl. 3). — 1S–11S. Справочник психиатра_правки-Шульман.indd 594 30.10.2015 11:21:45 Литература 595 WHO World Mental Health Surveys, 2008. Global Perspectives on the Epidemiology of Mental Disorders / Eds. R.C. Kessler, T.B. Ustun. — Geneva: WHO, 2008. — 698 p. Wilkinson R.G. Th e Impact of Inequality: how to make sick societies healthier. — N.Y.: New Press, 2005. Williams J.W., Mulro w C.D., Chiquette E. et al. A systematic review of newer pharmaco- therapies for depreddion in adults: evidence report summary. Clinical Guideline, part 2 // Ann. Intern. Med. — 2000. — Vol. 132. — P. 743–756. Wittchen H.-U., Jacobi F. Size and burden of mental disorders in Europe — a criti- cal review and appraisal studies // European Neuropsychopharm. — 2005. — Vol. 15. — P. 357–376. Справочник психиатра_правки-Шульман.indd 595 30.10.2015 11:21:45 |